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Abstract / Summary 
Candida is a fungus (yeast) that is generally regarded as a normal and harmless member of the 
oral microbiome in humans.  Should host defences against these commensals be compromised in 
any way then Candida can cause clinical signs and symptoms, which manifest as distinct forms 
of oral candidosis (candidiasis).  Candida albicans is the most frequently isolated candidal 
species from the oral cavity, although a range of non-C. albicans Candida species are being 
increasingly encountered.  The basic principle of the management of candidosis is to identify and 
eliminate any underlying host predisposing factor.  However, in many cases, antifungal therapy 
will also be required as part of initial management.  This article will provide an overview of the 
isolation, identification and pathogenicity of Candida species encountered within the mouth and 
relate these to clinical management of oral candidosis.  
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Introduction  
Candidosis has been described since the times of Hippocrates (circa 460 – 370 BC), being referred to as 
“a disease of the diseased’, which highlights the opportunistic nature of the infection and the primary role 
of a reduced host defence in its development.  Candida is a type of fungus (yeast), that is frequently 
encountered in the mouth of healthy individuals and as such this microorganism is considered to be a 
member of the normal oral microbiome. The incidence of oral candidal carriage within the general 
population has traditionally been reported to be between 35% -80%, depending on the specific cohort 
studied (1, 2).  However, these findings have historically been based on cultural studies.  More recently, 
the use of molecular detection methods would suggest that Candida species are in fact present in the 
mouths of all individuals (3).  In addition, other fungal species, including Saccharomyces, Geotrichum 
and Cryptococcus species have on rare occasions been isolated from the mouth (Table 1), but their 
numbers are generally limited and they have not been implicated in specific oral infection (4). 
It is important to recognise that oral candidosis is not a single infection entity, and traditionally, 
four distinct forms of primary oral candidosis are described based on clinical presentation (5). 
The reasons why a particular individual patient may present with one form of infection as 
opposed to another are unclear, especially since all forms are seemingly caused by the same 
fungal species.  It is likely that a combination of host factors and microbial factors will 
ultimately determine the occurrence of a particular form of oral candidosis. What is also evident 
is that Candida albicans, which is most often the cause of oral candidosis, is an extremely 
heterogeneous species, whose strains differ markedly, both phenotypically and genotypically. 
Thus, Candida strain variation could also be an influencing factor on whether an individual 
actually manages to clear the colonising strain or whether it is retained as a commensal. It is 
conceivable that strain variation could promote pathogenesis through elevated expression of 
virulence determinants and by affecting the nature of host immune responses.  On rare occasions 
Candida can enter the blood stream and be disseminated to many organs with resultant life 
threatening infection (5).  Such systemic candidal infection is beyond the scope of this article.    
Whilst Candida species are normally harmless residents of the mouth, when conditions alter to 
an environment that favours proliferation of Candida, a shift to a ‘pathogenic’ relationship with 
the host may occur. Infection with Candida is described in the literature as a candidosis 
(candidoses, pl) or candidiasis (candidiases, pl).  Both terms are widely used, although 
candidosis is preferred due to its consistent use of the ‘osis’ stem with the terminology for other 
fungal infections. The term Candida originates from the Latin word ‘candidus’, meaning white. 
 
Identity and pathogenicity 
The most prevalent Candida species recovered from both healthy and infected human mouths is 
C. albicans, and it is estimated that this species is responsible for over 80% of oral fungal 
isolates. In terms of prevalence, C. albicans is followed in descending order by C. glabrata, C. 
krusei, C. tropicalis, C. guilliermondii, C. kefyr and C. parapsilosis.  Even less frequently 
encountered are C. inconspicua, C. lusitaniae, C. norvegensis and C. rugosa.  In recent years, the 
importance of these non-Candida albicans Candida species in human disease has increasingly 
been recognised. Whilst these species typically lack the range of virulence factors encountered 
with C. albicans, they have come to prominence due to their enhanced resistance to antifungal 
agents. Candida dubliniensis was first described in 1995, following its co-isolation with C. 
albicans from cases of oral candidosis in HIV-infected individuals (7).  Since C. dubliniensis 
shares a number of unique phenotypic characteristics with C. albicans, its mis-identification as 
C. albicans, has probably occurred frequently.  
 The transition of Candida from a harmless commensal to a pathogen is complex and most likely 
relates to local environmental changes in the host that promote either increased growth of 
Candida or altered expression of its virulence factors.  It is becoming increasingly acknowledged 
that as well as interaction between host factors and Candida, the bacterial component of the oral 
microbiome is also involved in the development of oral candidosis (8).  When considering 
Candida virulence factors, it is important to note that a number of these do not directly induce 
damage to host tissues, but will influence lifestyle of Candida, which indirectly promote 
pathogenicity (9).  
 
In order to cause oral candidosis, Candida has to be retained within the mouth. Consequently, a 
key virulence attribute of Candida is its ability to adhere to host surfaces. In the mouth, this 
allows Candida to resist removal from the effects of salivary flow and swallowing. Adherence 
can be to the oral epithelium or surfaces of prosthetic devices including dentures and orthodontic 
appliances. In the case of oral epithelium, as cells are sloughed off during the constant 
replacement of the oral mucosa, Candida will be removed and swallowed. Therefore, its ability 
to grow on the surface at a rate that at least is in equilibrium to loss of cells is vital to its 
persistence. Furthermore, mucosal surfaces can readily be recolonised from chronic reservoirs of 
Candida on intra-oral devices, in particular acrylic dentures, the surfaces of which obviously 
lack the ability to overcome colonisation by renewal.  Once attached to host surfaces, Candida, 
and in particular C. albicans, can switch from yeast to filamentous forms, which may facilitate 
epithelial penetration.  This property, coupled with an increased resistance to phagocytosis will 
promote persistence of Candida in the mouth.  
 Destruction of host tissues by Candida might occur due to the physical effect of filamentous 
growth into tissues. However, the invading Candida release extracellular hydrolytic enzymes 
into the local environment which also lead to tissue damage (10).  The enzymes most frequently 
implicated in the virulence of C. albicans are secreted aspartyl proteinases (SAPs).  In addition 
to SAPs, enzymes categorised as phospholipases (PLs) are also viewed as virulence factors.  
.  
Isolation and identification of Candida from the oral cavity 
A variety of techniques that enable recovery of Candida from the oral tissues (4), including swab 
(11), oral rinse (12) and imprint (13) (Davenport 1970) have been developed (Table 2).  Each 
sampling method for microbial culture has its own particular advantages and disadvantages and 
as such the most appropriate technique for an individual patient is dependent on the lesion type 
and suspected clinical form of candidosis (4). 
 
When there is a defined lesion, a direct sampling approach, such as use of a swab or imprint is 
preferred, since both these methods will provide information on the organisms on the surface of 
the lesion itself.  A plain microbial swab can be directly applied to lesion tissue (Fig 1) and sent 
for culture.  Uptake of the swab is improved if it is dampened first and rotated 360° when on the 
tissues.  The imprint culture technique involves placement of a sterile foam–pad (ca 2.5 cm2), 
which has been dipped in sterile saline, onto the lesional tissues or intra-oral appliance for 30 
seconds (Fig 2). The imprint foam pad is then placed directly onto an agar plate in the clinic 
prior to being sent to the laboratory.        
 
Where no obvious mucosal lesion is present, then indirect sampling involving collection of 
whole saliva in a sterile universal container or an oral rinse method is more appropriate.  The oral 
rinse technique involves the patient holding 10 ml of sterile phosphate buffered saline (0.01 M, 
pH 7.2) in the mouth for 60 seconds. The rinse is then collected in a sterile universal container, 
which is then labeled and sent for culture (Fig 3).  The sample is concentrated (10-fold) by 
centrifugation prior to inoculation onto agar using a spiral plating system.  Growth is expressed 
as candidal colony forming units per ml (cfu/ml) of the rinse.  The quantitative nature of the oral 
rinse also permits differentiation between the level of up to 100 cfu/ml, which is considered to be 
‘commensal carriage’, and higher levels which can be regarded as ‘pathogenic’.     
 
Samples for Candida detection are traditionally inoculated onto Sabouraud dextrose agar (SDA) 
and incubated aerobically at 37ºC for 24-48 hours (13).  The vast majority of candidal species 
cultured on SDA will appear as white/cream colonies and therefore subsequent tests are required 
to identify isolates to species level (Fig 4).  Chromogenic media (Fig 5), on which various 
Candida species grow as different colony colours are now available.  These differential media 
provide presumptive identification of certain Candida species based on colony appearance and 
colour following primary culture. The advantage of such media is that the presence of multiple 
Candida species in a single sample can be determined, which may be important in selecting 
subsequent treatment options, in particular choice of antifungal therapy. 
 
Definitive identification of Candida can be made through a variety of supplemental tests usually 
involving evaluation of morphological and physiological characteristics of an isolate.  
Biochemical identification of Candida is primarily based on carbohydrate assimilation, with a 
range of commercial systems available to facilitate such tests.  Identification is determined by the 
profile of carbohydrates able to support growth of the test isolate.  Increasingly, molecular-based 
methods are being employed with a number of species-specific polymerase chain reaction (PCR) 
approaches for Candida being used (4).   
 
The presence of Candida on the mucosal surface of the mouth or an intra-oral appliance can 
easily be confirmed for the vast majority of cases of pseudomembranous candidosis and 
erythematous candidosis by use of one of microbial culture based techniques.  In contrast, a 
tissue biopsy is required for definitive diagnosis of chronic hyperplastic candidosis, since it is 
necessary to demonstrate invasion of the epithelium by Candida by histological staining using 
the periodic acid-Schiff (PAS) technique or Gomori’s methenamine silver stains. Molecular 
techniques have also been used to identify candidal species within formalin fixed paraffin 
embedded tissue (15).  
 
Antifungal agents 
Relatively few antifungal drugs are available compared with the wide range of antibiotics for 
bacterial infections, which probably reflects the difficulty involved in developing an agent with 
activity against a eukaryotic cell type without inherent problems of associated host toxicity.  
Antifungal drugs can be classified into four types according to mode of action and target; 1.  
Disruption of fungal cell membranes, as in polyene antifungals (nystatin and amphotericin); 2. 
Inhibition of ergosterol synthesis, in the azole group of antifungals (fluconazole and 
itraconazole); 3.  Inhibition of ß1,3 D-glucan synthetase enzymes in the echinocandin antifungals 
(caspofungin); 4.  Interference with RNA synthesis and DNA replication (flucytosine). 
 Polyenes were developed in the 1950s and were the first true antifungal agents.  These drugs are 
fungicidal and act by inducing cell membrane porosity following interaction with the ergosterol 
component of the membrane, and the subsequent effect of loss of cytoplasmic content.  Polyenes 
have a broad spectrum of antifungal activity, but due to their poor absorption through the gut 
their use in dentistry is limited to topical delivery.  Intravenous delivery of amphotericin is an 
option for serious life threatening forms of systemic candidal infection, but is associated with 
significant side effects and toxicity.  Until the advent of the azoles, polyenes were the only 
practical option for treatment of all forms of oral candidosis.  The efficacy of topical polyenes in 
the mouth is limited due to difficulty in maintaining sufficient levels of the antifungal agent in 
the environment of the candida.  This is further complicated by the unpleasant taste of polyenes, 
which stimulates salivary flow, thereby diluting salivary levels of the drug below therapeutic 
levels.  Pharmaceutical companies have now ceased manufacturing topical forms of 
amphotericin and all but one format (suspension) of nystatin.  Despite widespread use over the 
past six decades, the incidence of resistance to polyenes by Candida is rare, but can sometimes 
arise through a reduction in the ergosterol content of cell membranes (16).  
 
Azole antifungals became available for clinical use in the 1980s.  These drugs are fungistatic and 
act through interference with a fungal enzyme, lanosterol demethylase, which is key to the 
biosynthesis of ergosterol component of the cell membrane.  Miconazole is available in cream or 
ointment format and in combination with a steroid anti-inflammatory.  All these formats of 
miconazole can only be used topically.  In contrast, other azoles including ketoconazole, 
fluconazole and itraconazole, are well absorbed through the gut and were the first antifungals 
that could be administered systemically through oral administration.  However, ketoconazole is 
associated with significant toxicity, which restricts its clinical use and as such this drug will not 
be considered any further in this article.  Itraconazole and fluconazole are relatively safe and 
rarely associated with adverse reactions.  However, there is an important drug interaction 
between warfarin and azole antifungal agents, including miconazole even when delivered 
topically (17).  Warfarin is potentiated and concomitant use can result in serious bleeding and 
even death.  It is possible to use topical nystatin suspension in patients taking warfarin but, as 
described above, the clinical efficacy of this antifungal preparation is poor.  Consideration can be 
given to approaching the medical staff prescribing the warfarin to see if the patient can be 
provided with the newer alternative oral anticoagulant drug, dabigatran, since it does not interact 
with fluconazole.  However, the use of dabigatran instead of warfarin may not be appropriate or 
possible, which does create a dilema when trying to manage significant oral candidal infection in 
a patient taking warfarin. 
 
Another commonly encountered potential drug interaction involving azole antifungals is with 
statins.  A patient prescribed fluconazole should be instructed to refrain from taking their statin 
for the duration of antifungal therapy, usually only seven days.  Fluconazole is particularly 
appropriate for use in the treatment of oral candidosis since it is secreted in saliva at levels 
equivalent to those achieved in the blood.  Fluconazole is routinely prescribed for out-patients in 
capsule form, but is also available as a suspension if this format of delivery is required. In 
addition, fluconazole can be administered intravenously. 
 
Unfortunately, acquired resistance to azole antifungals has emerged in recent years and certain 
Candida species are also inherently resistant to these agents.  There are several mechanisms of 
azole resistance reported and include 1) an alteration in the chemical structure of demethylase 
enzyme, 2) removal of the azole from the cell by multidrug transporter pumps, 3) compensation 
by other sterol synthesis enzymes in membrane biosynthesis.  Even in the absence of a defined 
resistance mechanism, the in vitro susceptibility of a given Candida strain often does not often 
correlate with subsequent clinical outcome for patients with oral candidosis.  One possible 
explanation for this could relate to the phenotypic differences between planktonic and biofilm 
cultured cells, as it is the former that are most frequently used for in vitro antifungal 
susceptibility testing. 
 
Echinocandin antifungals and flucytosine do not have a role to play in the outpatient treatment of 
oral candidosis and will not be considered here. 
 
Oral candidoses 
The four distinct primary forms of oral candidosis comprise, pseudomembranous candidosis, 
acute erythematous candidosis, chronic erythematous candidosis (CEC) and chronic hyperplastic 
candidosis (CHC).  Pseudomembranous candidosis (thrush) was previously classified as being 
either acute or chronic based on duration of signs and symptoms.  However, more recently, 
distinction between the two has been dropped.  Any form of oral candidosis can be accompanied 
by the presence of angular cheilitis.  Each of these forms of candidal infection is associated with 
characteristic clinical signs and symptoms and a range of host predisposing factors (Table 3).  
 
The clinical presentation, diagnosis and management of each type of oral candidosis is described 
in detail below.  However, before describing specific issues related to each individual clinical 
form of candidosis, some general principles that apply to all need to be considered.  
Identification and subsequent correction of any underlying predisposing host factor is crucial in 
the management of oral candidosis.   
 
The medical history will reveal any already recognised predisposing factor.  However, 
assessment of the patient should routinely involve the following haematological tests; full blood 
count (FBC), serum ferritin, vitamin B12, folate.  Any abnormality in the FBC or haematinic 
deficiency needs to be investigated further and the cause identified.  Iron deficiency anaemia or 
pernicious anaemia are found relatively frequently in patients with candidosis and correction 
usually leads to resolution of infection.  The basis of this association is not clear but may be due 
in part to the involvement of iron or vitamain B12 in epithelial cell formation in the oral mucosa 
or antimicrobial aspects of the host defence systems.  Undiagnosed or poorly controlled diabetes 
is often an underlying problem in candidal infection and therefore blood glucose and 
haemoglobin A1c (HbA1c) need to be measured.  Establishment of good glycaemic control and 
maintenance of blood glucose (< 10 mmol/L) is key in the management of oral candidosis, but 
unfortunately many patients have difficulty achieving this.  Tobacco smoking is associated with 
oral candidosis, in particular chronic hyperplastic candidosis.  Any patient with a tobacco habit 
should be advised on smoking cessation. 
 
In some instances, a recognised predisposing factor cannot be eliminated, such as the essential 
use of immunosuppressive drug therapy in solid organ transplantation or presence of HIV.  In 
such circumstances the role of antifungal therapy in management of candidosis has special 
relevance.  
 
 
Pseudomembranous candidosis 
Pseudomembranous candidosis is synonymous with the term ‘oral thrush’ and is characterised by 
the presence of superficial white plaques that are easily removed by gentle scraping of the lesion 
(18) (Fig 6).  The ability to remove these plaques is an accepted diagnostic feature that 
differentiates pseudomembranous candidosis from the other forms of white patches that develop 
in the mouth.  Microscope examination of a stained smear taken from these plaques reveals fungi 
in yeast and filamentous forms, together with epithelial cells.  Alternatively, a swab from the 
white patches can be sent for culture and this can be used to identity the Candida species present. 
   
The pseudomembranous candidosis form of candidosis is most frequently associated with use of 
steroid therapy.  It is also found relatively frequently in neonates.  There is a direct relationship 
with immunodeficiency, and pseudomembranous candidosis is a recognised presenting feature 
and ongoing complication of leukaemia and HIV infection.  In such instances, long-term use of 
antifungal agents is often successful.   
 
The vast majority of cases of pseudomembranous candidosis seen in primary dental care will be 
due to the use of inhaled steroids.  Antifungal therapy in the form of fluconazole, 50mg, once 
daily for 7 days, with appropriate considerations (see above), should be prescribed.  This will 
reduce the candidal load to normal levels.  In addition, the patient should be instructed on the 
need to rinse their mouth with water following inhaler use.  This advice is now included on the 
inhaler product information leaflet.    
 
Acute erythematous candidosis 
Acute erythematous candidosis tends to develop as a consequence of a reduction in the levels of 
the bacterial component of the oral microflora following the receipt of broad spectrum 
antibiotics.  Unsurprisingly the condition is therefore often referred to as ‘antibiotic sore mouth’.  
Concomitant use of steroid therapy, particularly in inhaler form, may be an additional 
contributing factor as this can lead to local immunosuppression with a resulting overgrowth of 
Candida. 
 
A reduction of bacterial numbers in the oral cavity results in a lowering of microbial 
competition with Candida in terms of nutrition and adherence sites.  The clinical signs and 
symptoms of acute erythematous candidosis are therefore a direct consequence of an ecological 
shift from the normal homeostatic balance of the microbial community.  Acute erythematous 
candidosis presents as a painful reddened lesion on the dorsum of the tongue (Fig 7).  
Confirmation of the presence of Candida and their identity can be made by taking a swab or 
imprint for culture.  Cessation of antibiotic therapy results in a return to normal levels of 
bacteria, which subsequently resolves the candidosis without intervention.  If symptoms are 
significant then systemic fluconazole, 50mg once daily for seven days can be prescribed.    
 
Chronic erythematous candidosis 
Chronic erythematous candidosis is commonly referred to as Candida-associated denture 
stomatitis and presents as a reddening of the mucosa beneath the fitting surface of a denture (Fig 
8). The infection may develop under any acrylic denture or indeed intra-oral appliance, but is 
most often encountered on the palatal rather than the mandibular mucosa.  Principle host factors 
associated with this condition are inadequate oral hygiene, continuous wearing of the denture or 
the presence of a poor fitting denture (19).  Chronic erythematous candidosis is the most 
prevalent form of oral candidosis, with up to 75% of denture wearers having clinical signs of this 
condition, although often the individual is unaware of infection (20). 
 
Imprints or swabs taken from the fitting surface of the denture and the palatal mucosa can be 
used to confirm the presence of Candida following culture.  It is important to appreciate that the 
Candida are colonising the denture and not the mucosa.  Therefore, whilst the sample from the 
denture should yield candidal growth, sampling of the erythematous mucosa may be negative.   
 
The management of this form of candidosis is primarily focused on eradication of colonisation of 
denture.  As such, miconazole can be applied topically to the fitting surface of the denture and 
placed in the mouth.  The denture, if there are no metal components, should be removed whilst 
sleeping and placed in dilute hypochlorite (usually overnight).  Dentures with metal components 
should not be placed in hypochlorite, but soaked in chlorhexidine instead to avoid tarnishing of 
the metal.  Whilst of primary importance in the management of chronic eryhtematous candidosis, 
the denture hygiene measures described above should be instituted as an aspect of the treatment 
of all forms of oral candidosis since candidal colonization of the acrylic componenet of the 
denture acts as a chronic reservoir of Candida species that will lead to recurrence of infection 
within the mouth. 
 
Chronic hyperplastic candidosis (CHC)  
Characteristically, CHC appears as a thickened white plaque, most frequently at the commissural 
region of the mouth or on the dorsum of the tongue (Fig 9).  A smoking tobacco habit is almost 
universally present in patients with CHC.  Of concern with this infection is the proposed link 
with malignant change at lesional sites, although the role of Candida in carcinogenesis or the 
development of epithelial dyspasia remains unclear (21, 22).  It has been suggested that it may be 
helpful to provide a seven day course of systemic antifungal therapy prior to taking a biopsy of a 
suspicious lesion since any epithelia dysplasia subsequently observed in the biopsy material can 
be interpreted as “true” dysplasia rather than be due to the presence candida. (REF) 
 
Two clinical types of CHC have been described based on the lesion encountered.  Homogeneous 
CHC is described as having smooth and white lesions which are notably distinct from those of 
heterogeneous CHC where areas of erythema occur resulting in a nodular, speckled appearance.  
It has been suggested that heterogeneous lesions have the greater likelihood of malignant 
transformation (23).  In contrast with pseudomembranous candidosis, the white patch lesions of 
CHC do not rub off with gentle scraping.  The diagnosis of CHC is dependent on the histological 
examination of lesional biopsy material which will reveal invading Candida hyphae (24).  There 
will also be a chronic inflammatory response in the underlying connective tissues.  Uncertainty 
remains over whether candidal invasion is the primarily ecological factor of CHC or whether 
Candida infection is secondary to the presence of an altered epithelium. 
 Management of CHC should involve the prescribing of fluconazole 50 mg daily over a period of 
7-14 days depending on the severity of the lesions. (Fig 10).  In addition, the patient must stop 
their tobacco habit.  Failure to achieve smoking cessation will inevitably result in recurrence of 
infection.  Patients should be informed of the risk of malignant transformation. 
 
Secondary forms of oral candidosis 
Angular cheilitis presents as erythematous lesions at the angles of the mouth (Fig 11).  This form 
of candidosis may also be accompanied by the presence of Staphylococcus aureus or 
streptococcal species and therefore the exact role that Candida itself plays in the infection is 
difficult to ascertain (25).   Often, angular cheilitis occurs in patients with a pre-existing primary 
form of oral candidosis.  The elevated numbers of Candida within the oral cavity results in direct 
spread and colonisation of the angles of the mouth.  Treatment should involve identification and 
eradication of the cause of the oral candidosis.  If this is achieved, then the angular cheilitis 
should resolve.  Symptomatic treatment of the angles should involve the use of topical 
miconazole alone or in a combination format with hydrocortisone.      
 
Median rhomboid glossitis is a chronic condition with a distinct clinical presentation involving a 
symmetrically shaped lesion on the midline of the dorsum of the tongue.  Candida can be 
recovered from the surface and biopsy material. Tobacco smoking and the use of steroid inhalers 
seem to be predisposing host factors.  The role of Candida in this mucosal condition is supported 
by the observation that provision of systemic fluconazole often results in resolution of the 
clinical signs and symptoms. 
 Chronic mucocutaneous candidosis (CMC) is a particular condition where a range of superficial 
Candida infections of mucous membranes skin and nails are encountered.  The principle 
predisposing factor for CMC is congenital impaired cellular immunity against Candida. 
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 Table 1 Fungal species recovered from the human mouth. 
Candida species Non-candida species  
Candida albicans Paracoccidioides brasiliensis 
Candida glabrata Aspergillus species 
Candida tropicalis Cryptococcus neoformans 
Candida krusei Histoplasma capsulatum 
Candida lusitaniae Mucor species 
Candida dubliniensis Saccharomyces species 
Candida kefyr Geotrichum species 
Candida guilliermondii Rhizopus species 
Candida parapsilosis  
 
  
 Table 2  Sampling methods for recovery of Candida from the mouth. 
Sampling method Advantage Disadvantage 
Whole saliva Sensitive; viable organisms 
isolated 
Problems may occur with 
collection of sample; not site 
specific 
Oral rinse Quantitative; viable cells 
obtained 
Not site specific 
Swab Simple to use; viable cells 
isolated; site specific 
Not quantitative 
Smear Simple to use; not reliant on 
culture 
Viable cells not obtained; species 
identity not readily confirmed 
Imprint  Quantitative; viable cells 
obtained; site specific 
Some sites difficult to sample 
Biopsy Essential for chronic 
hyperplastic candidosis 
Invasive; not appropriate for 
other forms of candidosis 
 
  
 Table 3 Host related predisposing factors associated with oral candidosis. 
 
Local host factors 
● Intra-oral appliance (in particular, denture)  
● Steroid inhaler use 
● Reduced salivary flow (including post radiotherapy) 
● Carbohydrate rich diet 
Systemic host factors 
● New born or elderly 
● Endocrine disorders (in particular, diabetes) 
● Immuno-suppression or immunodeficiency  
● Broad spectrum antibiotic therapy 
● Nutritional deficiency 
● Auto-immune disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Swab. 
 
Figure 2.  Imprint. 
 
Figure 3 Oral rinse. 
 
Figure 4  Spiral plate on SDA. 
 
Figure 5  Chromagar. 
 
Figure 6.  Pseudomembranous candidosis. 
 
 
Figure 7. Acute erythematous candidosis. 
 
 
Figure 8.  Chronic eryhthematous candidosis. 
 
Figure 9 a.  CHC 
 
 
 
Figure 9 b. CHC  
 
 
Figure 10 a.  CHC 
 
 
 
Figure 10 b.  CHC 
 
 
Figure 11.  Angular chelitis. 
 
 
